Canaccord Genuity Maintains Buy on Intellia Therapeutics, Lowers Price Target to $49

Benzinga Newsdesk www.benzinga.com Negative 66.9%

Neg 66.9% Neu 0% Pos 0%

Canaccord Genuity analyst Whitney Ijem maintains Intellia Therapeutics (NASDAQ:NTLA) with a Buy and lowers the price target from $58 to $49.